Clinical Trial Update: A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update indicates EB-1020 is being studied for pediatric ADHD in Phase 2/3 and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• EB-1020

Snippet

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Attention-Deficit Hyperactivity Disorder(ADHD) | Phase 2, Phase 3 | Status: RECRUITING